At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 409 enrolled
Drug / intervention
Biological Vaccine VLA1553biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blinded Phase 3 Study to Demonstrate Lot-to-Lot Consistency of Three Lots of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Adults Aged 18 to 45 Years
In Brief
A Phase 3 clinical trial evaluating Biological Vaccine VLA1553 for Chikungunya Virus Infection. Completed, enrolled 409 participants across 12 sites.
Detailed Summary
This was a prospective, randomized, double-blinded, multicenter Phase 3 clinical study investigating three Lots of VLA1553 at the final dose. Overall 409 healthy subjects aged 18 to 45 years were randomized into the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChikungunya Virus Infection
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartFeb 2021
First PostedMar 2021
Primary CompletionJul 2021
Study CompletionJan 2022
TodayJul 2026
First PostedMar 8, 2021
Enrollment StartFeb 22, 2021
Primary CompletionJul 22, 2021
Study CompletionJan 26, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.3 years ago
Interventions
Biological Vaccine VLA1553biological
Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate